share_log

Comparing BioAffinity Technologies (NASDAQ:BIAF) & MaxCyte (NASDAQ:MXCT)

Comparing BioAffinity Technologies (NASDAQ:BIAF) & MaxCyte (NASDAQ:MXCT)

比较 BioAffinity Technologies(纳斯达克股票代码:BIAF)和 MaxCyte(纳斯达克
Defense World ·  2023/01/14 14:21

MaxCyte (NASDAQ:MXCT – Get Rating) and bioAffinity Technologies (NASDAQ:BIAF – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

MaxCyte(纳斯达克股票代码:MXCT — 获取评级)和BioAffinity Technologies(纳斯达克股票代码:BIAF — 获取评级)都是小型医疗公司,但哪只股票更好?我们将根据两家公司的收益、风险、估值、盈利能力、机构所有权、股息和分析师建议的实力进行比较。

Analyst Ratings

分析师评级

This is a summary of recent ratings and recommmendations for MaxCyte and bioAffinity Technologies, as reported by MarketBeat.

据MarketBeat报道,这是MaxCyte和BioAffinity Technologies的最新评级和推荐摘要。

Get
获取
MaxCyte
MaxCyte
alerts:
警报:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte 0 0 1 0 3.00
bioAffinity Technologies 0 0 0 0 N/A
卖出评级 保持收视率 买入评级 强劲的买入评级 评分分数
MaxCyte 0 0 1 0 3.00
生物亲和性技术 0 0 0 0 不适用

MaxCyte currently has a consensus target price of $9.00, suggesting a potential upside of 63.93%. Given MaxCyte's higher probable upside, equities research analysts clearly believe MaxCyte is more favorable than bioAffinity Technologies.

MaxCyte目前的共识目标价为9.00美元,这表明潜在的上涨空间为63.93%。鉴于MaxCyte的上行空间可能更高,股票研究分析师显然认为MaxCyte比BioAffinity Technologies更有利。

Profitability

盈利能力

This table compares MaxCyte and bioAffinity Technologies' net margins, return on equity and return on assets.
该表比较了MaxCyte和BioAffinity Technologies的净利润率、股本回报率和资产回报率。
Net Margins Return on Equity Return on Assets
MaxCyte -56.29% -9.12% -8.21%
bioAffinity Technologies N/A N/A N/A
净利润 股本回报率 资产回报率
MaxCyte -56.29% -9.12% -8.21%
生物亲和性技术 不适用 不适用 不适用

Valuation & Earnings

估值与收益

This table compares MaxCyte and bioAffinity Technologies' revenue, earnings per share (EPS) and valuation.

该表比较了MaxCyte和BioAffinity Technologies的收入、每股收益(EPS)和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MaxCyte $33.89 million 16.56 -$19.08 million ($0.23) -23.87
bioAffinity Technologies N/A N/A -$6.33 million N/A N/A
总收入 价格/销售比率 净收入 每股收益 市盈率
MaxCyte 3,389 万美元 16.56 -1,908 万美元 (0.23 美元) -23.87
生物亲和性技术 不适用 不适用 -633 万美元 不适用 不适用

bioAffinity Technologies has lower revenue, but higher earnings than MaxCyte.

BioAffinity Technologies的收入较低,但收益高于MaxCy

Insider and Institutional Ownership

内部所有权和机构所有权

66.7% of MaxCyte shares are owned by institutional investors. Comparatively, 2.4% of bioAffinity Technologies shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

66.7%的MaxCyte股票由机构投资者持有。相比之下,2.4%的BioAffinity Technologies股票由机构投资者持有。5.1%的MaxCyte股票由内部人士持有。强大的机构所有权表明,对冲基金、捐赠基金和大型基金经理认为一家公司已为长期增长做好了准备。

Summary

摘要

MaxCyte beats bioAffinity Technologies on 5 of the 9 factors compared between the two stocks.

比较两只股票的9个因素中,MaxCyte在9个因素中的5个上击败了BioAffinity Tech

About MaxCyte

关于 MaxCyte

(Get Rating)

(获取评分)

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MaxCyte, Inc. 是一家全球生命科学公司,从事下一代细胞疗法的发现、开发和商业化。其产品包括Expert atX,一种用于中小型转染的静态电穿孔仪器;exPert stX,一种用于蛋白质生产和药物开发的流式电穿孔,以及用于基于细胞的检测的治疗靶点的表达;exPert GtX,一种用于治疗应用中大规模转染的流式电穿孔;以及用于超大体积细胞工程的eXpert vLX。该公司还提供用于处理和电穿孔细胞的一次性加工组件 (PA);以及支持 PA 的附件,例如电穿孔缓冲液和软件协议。该公司成立于 1998 年,总部位于马里兰州罗克维尔。

About bioAffinity Technologies

关于生物亲和性技术

(Get Rating)

(获取评分)

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

生物技术公司BioAffinity Technologies, Inc. 从事非侵入性诊断测试和靶向癌症疗法的开发。该公司提供用于早期发现肺癌的诊断测试CyPath lung。它还研究在细胞水平上治疗癌症的靶向疗法。该公司成立于2014年,总部位于德克萨斯州的圣安东尼奥。

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.

接收 MaxCyte Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收MaxCyte及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发